In this study, Dr. Niti Goel shows the under-reporting of race & ethnicity in publications of #psoriaticarthritis clinical trials 🧐Participant diversity is important to consider since different races & ethnicities may respond differently to therapies #ACR22 @RheumNow ABST0090 https://t.co/BzHpuHYVI5

Post hoc analysis from the SELECT-PsA 1 trial by Dr. @DrLauraCoates and team: 💊Pts on UPA showed greater improvement from BL in RAPID3 vs. ADA in all visits 💊Pts on UPA had better responses in all assessments vs. PBO Reassuring data. #ACR22 @RheumNow ABST0192 https://t.co/NgeUU5bPPf

Abstr 0383 evaluated the use of previously developed AI algorithm to detect sacroiliitis in a new axSpA cohort. The neural network achieved -Sensitivity 82%; specificity 81% -PPV 0.89; NPV 0.70 https://t.co/PDSsiMIQUc @RheumNow #ACR22 #AI #MachineLearning #AxSpA https://t.co/mXUHUowGhQ

• Analysis of the Performance of an Artificial Intelligence Algorithm for the Det…

Abstr #0195 examined acceptance of Virtual Reality among pts w/ rheumatic diseases (RD) - VR naïve & experienced were willing to use VR to manage their RD - VR experienced pts had ↑ % of perceived usefulness & anticipated enjoyment of VR in dx and mgmt of RD @RheumNow #ACR22 https://t.co/r7X8Kqp8UN

Abst0338 #ACR22 Transition from CLE to SLE 324 cases of incident cutaneous lupus, mean f/u 8 years 26 pts developed SLE. 5.2% transition by 5 years, <3% risk every 5 yrs from 5-20 years Risk factors: SCLE, younger age, recent diagnosis @RheumNow #ACRBest https://t.co/JFcUIkfA9n

Year in Review #ACR22 Pre-expos PPx for COVID! Tix-Cil (Evusheld): risk reduction 77% Cardiac AES 0.6% vs placebo 0.2% Only 3.3% were on immunosuppression But Israeli study with immunosuppressed: 92% half as likely to be hospitalized or die 1/2 less infections @RheumNow

Ab1291 #ACR22: 🔥Ignite🔥 @DavidLeverenz: Constructed a model to identify telehealth visits - PPV 0.8, sensitivity 0.39 - better than existing practice (PPV 0.77) Predictors: age, diagnoses, medications, RAPID3, provider preference for 💻🩺 3 mo pilot program predictive @RheumNow https://t.co/Iey87SVGv4

Very important point about statin induced myopathy by Dr. Christopher-Stine. If 1) history of statin exposure, 2) typical symptoms of myositis 3) HMGCR ab positive — do NOT need biopsy and can treat as statin associated necrotizing autoimmune myopathy! @RheumNow #ACR22 https://t.co/VHxPRkCWwj

Among ANCA-vasculitis hospitalizations, A Fib found to be most common CV condition. Females had fewer CV complications, lower in-hospital mortality & shorter length of stay compared to males. Abs 0434 #ACR22 https://t.co/2IikApUdvE https://t.co/16ggVScs3a

• Sex Based Differences in Cardiovascular Conditions Associated with Anti-neutrop…

SELECT-AXIS 2 subgroup analysis. UPA demonstrated improved efficacy vs PBO at Wk 14 across all evaluated subgroups of pts with bDMARD-IR AS. No new safety signals. @XBaraliakos et al, Abs 0414 #ACR22 https://t.co/lTfm68XlEY https://t.co/PaWdrOljMO

• Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis wit…

Do you check ANCAs in your ILD pts? Abs 0438 at #ACR22 suggests you should! @RheumNow https://t.co/W8rRAdWFQh https://t.co/RQfcQQUVzI

• Characterization of Interstitial Lung Disease in the Presence of Antineutrophil…

Headed to the #ACR22 Fellows in Training (FIT) session for a round table on keeping up with the medical literature! As usual, updated handout for this year 🤓 @MithuRheum Wish I had thought to ask you for help w/my graphics-game! Not my strength hahaha #ACRAmbassador https://t.co/Tg4ZT262rU

Very cool initiative @Robsonjo4 1. I love patient reported outcomes (PROs) 2. I think we under-appreciate how much steroids affect our patients quality of life Looking forward to seeing this live! #ACR22 #Vasculitis22 @RheumNow https://t.co/1akO1k7VgU

Interesting study about causes of death in GCA I never know what to make of these; our pts typically die of the usual things (cancer, CVD) and have increased risks of infection (due to treatment) Is there USA data about this? #ACRAmbassador #ACR22 https://t.co/ZMOSD7lYGL

Regional Winners (people's choice award goes to North America tumoral calcinosis) #ACR22 Image Competition @rheumnow https://t.co/y7dDHc75PQ